NAS:WGS (USA)
Â
Ordinary Shares - Class A
$
69.82
+1.15 (+1.67%)
10:08 PM EST
Business Description
GeneDx Holdings Corp
NAICS : 621511
SIC : 8734
ISIN : US81663L2007
Share Class Description:
WGS: Ordinary Shares - Class ATotal Employee Number:
1,300Description
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.02 | |||||
Equity-to-Asset | 0.5 | |||||
Debt-to-Equity | 0.66 | |||||
Debt-to-EBITDA | -4.06 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 1.78 | |||||
Beneish M-Score | -2.38 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -13.3 | |||||
3-Year Book Growth Rate | -21.2 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 21.18 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 79.24 | |||||
9-Day RSI | 72.5 | |||||
14-Day RSI | 67.12 | |||||
3-1 Month Momentum % | -19.41 | |||||
6-1 Month Momentum % | -63.05 | |||||
12-1 Month Momentum % | -44.82 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.09 | |||||
Quick Ratio | 2.95 | |||||
Cash Ratio | 1.95 | |||||
Days Inventory | 33.23 | |||||
Days Sales Outstanding | 50.5 | |||||
Days Payable | 19.3 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -35.4 | |||||
Shareholder Yield % | -6.82 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 69.56 | |||||
Operating Margin % | -7.84 | |||||
Net Margin % | -17.58 | |||||
EBITDA Margin % | -9.36 | |||||
FCF Margin % | -6.47 | |||||
OCF Margin % | -2.1 | |||||
ROE % | -28.01 | |||||
ROA % | -15.98 | |||||
ROIC % | -11.68 | |||||
3-Year ROIIC % | -1480.49 | |||||
ROC (Joel Greenblatt) % | -92.53 | |||||
ROCE % | -16.88 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 1837.37 | |||||
PE Ratio without NRI | 1108.25 | |||||
PS Ratio | 4.61 | |||||
PB Ratio | 8.15 | |||||
Price-to-Tangible-Book | 19.29 | |||||
EV-to-EBIT | -30.53 | |||||
EV-to-Forward-EBIT | -33.02 | |||||
EV-to-EBITDA | -49.94 | |||||
EV-to-Revenue | 4.68 | |||||
EV-to-Forward-Revenue | 4.35 | |||||
EV-to-FCF | -72.26 | |||||
Price-to-GF-Value | 0.98 | |||||
Price-to-Graham-Number | 30.76 | |||||
| Price-to-Net-Current-Asset-Value | 112.61 | |||||
Earnings Yield (Greenblatt) % | -3.28 | |||||
FCF Yield % | -1.38 |
GeneDx Holdings Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
GeneDx Holdings Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-28 08:30 | In 122 days | ||
| Third quarter earnings results for 2026 | 2026-10-28 | In 121 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-29 08:30 | In 31 days | ||
| Second quarter earnings results for 2026 | 2026-07-29 | In 30 days | ||
| General meeting for 2026 | 2026-06-18 09:00 | 56.42 (-6.74%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 08:00 | 51.80 (-1.65%) | ||
| First quarter earnings conference call for 2026 | 2026-05-04 16:30 | 65.38 (+3.12%) | ||
| First quarter earnings results for 2026 | 2026-05-04 | 65.38 (+3.12%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-23 08:30 | 82.06 (-8.03%) | ||
| Annual report for 2025 | 2026-02-23 | 82.06 (-8.03%) |
Show
Entries
Guru Commentaries on NAS:WGS
No articles.
Press Release
Articles on GeneDx Holdings Corp
No articles.
Headlines
See More- 1
Jun 18, 2026
GeneDx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against GeneDx Holdings Corp. - WGS
Benzinga • 9:54am
Jun 12, 2026
WGS INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026
Benzinga • 9:05am
Jun 11, 2026
WGS Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the GeneDx Holdings Corp. Class Action Lawsuit
Benzinga • 12:57pm
Jun 08, 2026
Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against GeneDx Holdings Corp. and Encourages Investors to Contact the Firm
Benzinga • 4:48pm
Jun 04, 2026
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers